Fig. 4: APOH increases the MUFA-PLs/MUFA-ePLs to inhibit Ferroptosis.

A Cell viability of MEFs cultured in Scm and then changed medium to Rcm or not, treated with or without Fatostatin A (Fato, 5 μM) for 12 h before treatment with RSL3 (0.15 μM) and/or Lip-1 (1 μM) for 24 h. B Cell viability of MEFs cultured in Scm and then changed medium to 5% Scm + 5% Rcm, 5% Scm + APOH (120 μg/mL) or not, treated with or without Fato (5 μM) for 12 h before treatment with RSL3 (0.225 μM) and/or Lip-1 (1 μM) for 24 h. C Relative levels of differentially altered MUFA-PLs/MUFA-ePLs of MEFs cultured in Scm, Rcm, 5% Scm + 5% Rcm, and 5% Scm + APOH (120 μg/mL). MUFA-PLs were normalized to the corresponding mean value. n = 4 independent repeats. D, E Western blot analysis of the protein levels of SCD1 in MEFs cultured in Scm and in cells in which the medium was changed from Scm to Rcm for the indicated time (D) or to 5% Scm + 5% Rcm or 5% Scm + APOH (120 μg/mL) (E). (F) Cell viability of MEFs cultured in Scm changed medium to 5% Scm + 5% Rcm or 5% Scm + APOH (120 μg/mL) treated with or without MK-8245 (80 μM) for 24 h before treatment with RSL3 (0.3 μM). Western blot is representative of three biological replicates. Data are presented as mean ± s.d., n = 3 independent repeats (A, B). n = 4 independent repeats (C). Unpaired, two-tailed t-test; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. NS not significant.